Article Text

Download PDFPDF
Venous Thromboembolism in Patients Receiving Extended Pharmacologic Prophylaxis After Robotic Surgery for Endometrial Cancer
  1. Josephine S. Kim, MD*,,
  2. Kathryn A. Mills, MD*,,
  3. Julia Fehniger, MD*,,
  4. Chuanhong Liao, MS,
  5. Jean A. Hurteau, MD,
  6. Carolyn V. Kirschner, MD,
  7. Nita K. Lee, MD, MPH*,
  8. Gustavo C. Rodriguez, MD,
  9. S. Diane Yamada, MD*,
  10. Elena S. Diaz Moore, MD and
  11. Meaghan E. Tenney, MD*
  1. *Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago Medicine, Chicago, IL;
  2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, NorthShore University HealthSystem, Evanston, IL; and
  3. Department of Public Health Sciences, University of Chicago, Chicago, IL.
  1. Address correspondence and reprint requests to Josephine S. Kim, MD, University of Chicago Medicine, 5841 S Maryland Ave MC 2050, Chicago, IL 60637. E-mail: jkim9@bsd.uchicago.edu.

Abstract

Objective This study aims to determine the rate of postoperative venous thromboembolism (VTE) in endometrial cancer patients undergoing robotic hysterectomy with or without extended pharmacologic VTE prophylaxis.

Methods/Materials A retrospective chart review of women undergoing robotic hysterectomy with or without other procedures for endometrial cancer from January 2010 to February 2015 was conducted at 2 institutions. Charts were manually abstracted, and rates of VTE within 30 and 60 days after surgery were determined. Patients were then stratified by those who did and did not receive extended VTE prophylaxis.

Results A total of 403 patients were included, of which 367 patients (91%) received extended pharmacologic prophylaxis and 36 patients (9%) did not. Low molecular weight heparin prescriptions ranged from 7 to 30 days. Patients receiving extended prophylaxis (EP) were older (63 ± 11 vs 57 ± 12; P = 0.004), more frequently underwent lymphadenectomy (67% vs 34%; P < 0.001), and had higher-grade tumors compared with patients not receiving EP. Overall 30-day and 60-day VTE rates were 0.7% and 1.2%, respectively. There were no significant differences in 30-day and 60-day VTE rates among patients that did and did not receive EP, although a trend toward lower VTE rates in the EP group was observed (30-day rates 0.5% vs 2.8% respectively, P = 0.25; 60-day rates 0.8% vs 5.6%, P = 0.07).

Conclusions In this study, 30-day and 60-day VTE rates after minimally invasive surgery for endometrial cancer were low. Rates were also similar to those of previous reports in this setting in which the majority of patients did not receive extended VTE prophylaxis. Given the consistent finding that postoperative VTE in this population is rare regardless of prophylaxis use and the variability in practice patterns for VTE prophylaxis, the development of best practice guidelines for EP use specific to this setting is warranted.

  • endometrial cancer
  • venous thromboembolism
  • robotic hysterectomy

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.